Global AI Lung Screening System Market Strategic Research Report

Scope of the Report

The global AI Lung Screening System market size is predicted to grow from US$ 329 million in 2025 to US$ 755 million in 2032; it is expected to grow at a CAGR of 12.6% from 2026 to 2032.

AI Lung Screening System is an integrated software-driven solution that supports early detection and risk stratification of lung cancer—primarily by analyzing low-dose CT (LDCT) scans in screening or incidental nodule workflows. The system typically performs automated lung nodule detection, segmentation, volumetry, growth tracking, malignancy risk scoring, and structured reporting, aiming to reduce radiologist workload, improve consistency, and standardize follow-up recommendations. In practice, it functions as a clinical decision support layer within radiology operations: it flags suspicious findings, prioritizes worklists, and helps quantify change over time. Commercially, “system” usually refers to a deployable product package (software + workflow integration + validation/regulatory package), rather than an algorithm alone, and is increasingly delivered as a platform with continuous model updates, audit trails, and performance monitoring.

From a multi-angle segmentation standpoint, the market can be parameterized by: (1) Clinical scenario: population LDCT screening vs incidental pulmonary nodules; (2) Algorithmic functions: detection-only, detection+volumetry, full risk scoring (e.g., malignancy probability), and longitudinal tracking; (3) Deployment: on-premise server, private cloud, public cloud/SaaS, or hybrid; (4) Integration depth: standalone viewer vs PACS/RIS embedded workflow with structured reporting; (5) Regulatory class & claims: CAD support vs triage vs quantified decision support. Additional quantitative “type” parameters include supported CT slice thickness, acceptable dose range, nodule size range (e.g., ≥3 mm), sensitivity at fixed false-positive rates, throughput (studies/hour), and interoperability standards (DICOM, HL7/FHIR).

In transaction terms, pricing commonly follows (a) annual subscription per site, (b) per-scan fee, or (c) enterprise license tied to volume tiers, with separate charges for integration, validation support, and service-level agreements. Procurement often runs through hospital IT/security reviews and radiology leadership, with pilots (3–6 months) preceding multi-year contracts. Key trends include tighter workflow embedding (worklist triage + structured reporting), expansion from single-task CAD to end-to-end nodule management, growing emphasis on generalizability and bias control across scanners and populations, and integration of multimodal data (clinical risk factors, prior imaging) to improve risk stratification. As screening volumes rise and radiologist shortages persist, vendors that can prove reduced recall burden, stable false-positive control, and seamless integration are best positioned for durable share gains.

This report presents a comprehensive overview of the global AI Lung Screening System market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Lung Cancer Early Screening
• Pulmonary Nodule Detection & Tracking
• High-Risk Population Screening
• Incidental Lung Finding Screening
• Others

Segment by Imaging Modality & Data Source

• LDCT-based Screening System
• Standard Chest CT AI System
• Others

Segment by Deployment & Integration Model

• On-premise
• Private Cloud (Hospital-owned Cloud)
• Public Cloud / SaaS
• Others

Segment by Application

• Medical Institutions
• Great Health Scene

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global AI Lung Screening System market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Medical Institutions, Great Health Scene evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact